A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Sato Y, Ohnuma H, Hirakawa M, Takahashi M, Osuga T, Okagawa Y, Murase K, Takada K, Kawano Y, Iyama S, Hayashi T, Sato T, Miyanishi K, Takimoto R, Kobune M, Okita K, Mizuguchi T, Furuhata T, Hirata K, Kato J.
Sato Y, et al. Among authors: furuhata t.
Cancer Chemother Pharmacol. 2015 Mar;75(3):587-94. doi: 10.1007/s00280-014-2672-9. Epub 2015 Jan 11.
Cancer Chemother Pharmacol. 2015.
PMID: 25577134
Clinical Trial.